Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis
Autori
Nobili, PaolaSHEN, Weida
Milicevic, Katarina
Bogdanović Pristov, Jelena
Audinat, Etienne
Nikolic, Ljiljana
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Epilepsy and multiple sclerosis (MS), two of the most common neurological diseases, are
characterized by the establishment of inflammatory environment in the central nervous
system that drives disease progression and impacts on neurodegeneration. Current
therapeutic approaches in the treatments of epilepsy and MS are targeting neuronal
activity and immune cell response, respectively. However, the lack of fully efficient
responses to the available treatments obviously shows the need to search for novel
therapeutic candidates that will not exclusively target neurons or immune cells.
Accumulating knowledge on epilepsy and MS in humans and analysis of relevant
animal models, reveals that astrocytes are promising therapeutic candidates to target
as they participate in the modulation of the neuroinflammatory response in both diseases
from the initial stages and may play an important role in their development. Indeed,
astrocytes respond to reactive immune cells and contribute to th...e neuronal hyperactivity in
the inflamed brain. Mechanistically, these astrocytic cell to cell interactions are
fundamentally mediated by the purinergic signalling and involve metabotropic P2Y1
receptors in case of astrocyte interactions with neurons, while ionotropic P2X7
receptors are mainly involved in astrocyte interactions with autoreactive immune cells.
Herein, we review the potential of targeting astrocytic purinergic signalling mediated by
P2Y1 and P2X7 receptors to develop novel approaches for treatments of epilepsy and MS
at very early stages.
Ključne reči:
astroglia / disease / intercellular interaction / neuroinflammation / P2X7 / P2Y1Izvor:
Frontiers in Pharmacology, 2022, 13, 900337-Izdavač:
- Frontiers Media
Finansiranje / projekti:
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200007 (Univerzitet u Beogradu, Institut za biološka istraživanja 'Siniša Stanković') (RS-200007)
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200178 (Univerzitet u Beogradu, Biološki fakultet) (RS-200178)
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200053 (Univerzitet u Beogradu, Institut za multidisciplinarna istraživanja) (RS-200053)
- Grants from European Commission (H2020 MSCA-ITN EU-GliaPhD No. 72205)
- Agence Nationale de la Recherche (contract numbers: ANR-19-CE16-0018-03 and ANR-20CE16-0003-02)
- Grants from Science and Technology Department of Zhejiang Province (2018C37131)
- Scientific Research Foundation for Returned Scholars of Hangzhou City (2019)
Institucija/grupa
Institut za multidisciplinarna istraživanjaTY - JOUR AU - Nobili, Paola AU - SHEN, Weida AU - Milicevic, Katarina AU - Bogdanović Pristov, Jelena AU - Audinat, Etienne AU - Nikolic, Ljiljana PY - 2022 UR - http://rimsi.imsi.bg.ac.rs/handle/123456789/1813 AB - Epilepsy and multiple sclerosis (MS), two of the most common neurological diseases, are characterized by the establishment of inflammatory environment in the central nervous system that drives disease progression and impacts on neurodegeneration. Current therapeutic approaches in the treatments of epilepsy and MS are targeting neuronal activity and immune cell response, respectively. However, the lack of fully efficient responses to the available treatments obviously shows the need to search for novel therapeutic candidates that will not exclusively target neurons or immune cells. Accumulating knowledge on epilepsy and MS in humans and analysis of relevant animal models, reveals that astrocytes are promising therapeutic candidates to target as they participate in the modulation of the neuroinflammatory response in both diseases from the initial stages and may play an important role in their development. Indeed, astrocytes respond to reactive immune cells and contribute to the neuronal hyperactivity in the inflamed brain. Mechanistically, these astrocytic cell to cell interactions are fundamentally mediated by the purinergic signalling and involve metabotropic P2Y1 receptors in case of astrocyte interactions with neurons, while ionotropic P2X7 receptors are mainly involved in astrocyte interactions with autoreactive immune cells. Herein, we review the potential of targeting astrocytic purinergic signalling mediated by P2Y1 and P2X7 receptors to develop novel approaches for treatments of epilepsy and MS at very early stages. PB - Frontiers Media T2 - Frontiers in Pharmacology T1 - Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis SP - 900337 VL - 13 DO - 10.3389/fphar.2022.900337 ER -
@article{ author = "Nobili, Paola and SHEN, Weida and Milicevic, Katarina and Bogdanović Pristov, Jelena and Audinat, Etienne and Nikolic, Ljiljana", year = "2022", abstract = "Epilepsy and multiple sclerosis (MS), two of the most common neurological diseases, are characterized by the establishment of inflammatory environment in the central nervous system that drives disease progression and impacts on neurodegeneration. Current therapeutic approaches in the treatments of epilepsy and MS are targeting neuronal activity and immune cell response, respectively. However, the lack of fully efficient responses to the available treatments obviously shows the need to search for novel therapeutic candidates that will not exclusively target neurons or immune cells. Accumulating knowledge on epilepsy and MS in humans and analysis of relevant animal models, reveals that astrocytes are promising therapeutic candidates to target as they participate in the modulation of the neuroinflammatory response in both diseases from the initial stages and may play an important role in their development. Indeed, astrocytes respond to reactive immune cells and contribute to the neuronal hyperactivity in the inflamed brain. Mechanistically, these astrocytic cell to cell interactions are fundamentally mediated by the purinergic signalling and involve metabotropic P2Y1 receptors in case of astrocyte interactions with neurons, while ionotropic P2X7 receptors are mainly involved in astrocyte interactions with autoreactive immune cells. Herein, we review the potential of targeting astrocytic purinergic signalling mediated by P2Y1 and P2X7 receptors to develop novel approaches for treatments of epilepsy and MS at very early stages.", publisher = "Frontiers Media", journal = "Frontiers in Pharmacology", title = "Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis", pages = "900337", volume = "13", doi = "10.3389/fphar.2022.900337" }
Nobili, P., SHEN, W., Milicevic, K., Bogdanović Pristov, J., Audinat, E.,& Nikolic, L.. (2022). Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis. in Frontiers in Pharmacology Frontiers Media., 13, 900337. https://doi.org/10.3389/fphar.2022.900337
Nobili P, SHEN W, Milicevic K, Bogdanović Pristov J, Audinat E, Nikolic L. Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis. in Frontiers in Pharmacology. 2022;13:900337. doi:10.3389/fphar.2022.900337 .
Nobili, Paola, SHEN, Weida, Milicevic, Katarina, Bogdanović Pristov, Jelena, Audinat, Etienne, Nikolic, Ljiljana, "Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis" in Frontiers in Pharmacology, 13 (2022):900337, https://doi.org/10.3389/fphar.2022.900337 . .